We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Polyplus-Transfection Launches Transfection Reagent for DNA and siRNA
Product News

Polyplus-Transfection Launches Transfection Reagent for DNA and siRNA

Polyplus-Transfection Launches Transfection Reagent for DNA and siRNA
Product News

Polyplus-Transfection Launches Transfection Reagent for DNA and siRNA


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Polyplus-Transfection Launches Transfection Reagent for DNA and siRNA"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Polyplus-transfection has announced the launch of jetPRIME ™, a new reagent for DNA and siRNA transfection.

jetPRIME™ brings pharmaceutical and biotechnology researchers a number of advantages for day-to-day transfection experiments.

The reagent may be used for DNA as well as siRNA transfection in order to conduct transient gene expression studies and gene silencing by RNA interference. jetPRIME™ is efficient regardless of the nucleic acid delivered and gentle to cells because it uses smaller amounts of both nucleic acid and reagent compared to most reagents on the market. Furthermore, jetPRIME™ is adapted to co-transfection of DNA and siRNA.

"Today's announcement of jetPRIME™ brings a significant new extension to our range and demonstrates Polyplus-transfection's ability to develop powerful transfection reagents," said Frédéric Perraud, CEO of Polyplus-transfection. "It also shows our commitment to continually improve our core business - the development of innovative solutions for transfection and therapeutic nucleic acid delivery."
Advertisement